At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Characterize LY3314814 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of LY3314814 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Lanabecestat, Simvastatin, and 2 other interventions for Healthy. Completed, enrolled 82 participants across 2 sites.
Detailed Summary
The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study
Study Details
Timeline
Interventions
50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
20 mg simvastatin will be administered orally as 1 × 20-mg tablet
500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
5 mg donepezil will be administered orally as 1 × 5-mg tablet
50 mg lanabecestat will be administered orally as 1 × 50-mg tablet